Skip to main content


A report in JAMA - Internal Medicine[1] raises important safety concerns about calcium channel blockers, one of the most widely prescribed classes of antihypertensives used world-wide. In the population-based case-control study by Li et al, particip...
  1.   Tuesday, 06 August 2013
  2.   Hypertension
  3. 0 Comments
As reported on UKidney, earlier in July 2013, Jamal et al published a systematic review comparing calcium-based phosphate binders with non-calcium-based phosphate binders in terms of their impact on cardiovascular outcomes. This pivotal wor...
  1.   Monday, 29 July 2013
  2.   General nephrology
  3. 2 Comments
Researchers from the University of Toronto and the University of Alberta add to existing data that calcium-based phosphate binders are harmful compared to binders that do not contain calcium. An updated systematic review on this topic that appears in...
  1.   Monday, 22 July 2013
  2.   General nephrology
  3. 0 Comments
Top-line results for the SAVOR trial were announced this week in which Saxagliptin (Onglyza, Bristol-Myers Squibb/AstraZeneca) failed to demonstrate superiority over placebo in reducing a composite end point of cardiovascular death, nonfatal MI,...
  1.   Friday, 21 June 2013
  2.   General nephrology
  3. 0 Comments
The High Impact Clinical Trials Session at this year's American Society of Nephrology Renal Week was the site of one of the most important and exciting nephrology developments to materialize in years. Researchers presented the results of a Phase 3 st...
  1.   Saturday, 03 November 2012
  2.   General nephrology
  3. 3 Comments
Jordan Weinstein doesn't have any blog post yet.
Unable to load tooltip content.